Luye Pharma GroupFRA:LUP +3.03%47 Current Ratio is 1.53 as of Dec. 2025, which is 9% above its 10-year median of 1.40. GuruFocus rates FRA:LUP with a GF Score™ of 47/100 and a GF Value™ of €0.32 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 997 Drug Manufacturers companies, Luye Pharma Group ranks worse than 64.79% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Luye Pharma Group's current ratio for the quarter that ended in Dec. 2025 was 1.53.
Luye Pharma Group has a current ratio of 1.53. It generally indicates good short-term financial strength.
The historical rank and industry rank for Luye Pharma Group's Current Ratio or its related term are showing as below:
FRA:LUP'
s Current Ratio Range Over the Past 10 Years
Min: 1.06 Med: 1.4 Max: 2.22
Current: 1.53
During the past 13 years, Luye Pharma Group's highest Current Ratio was 2.22. The lowest was 1.06. And the median was 1.40.
FRA:LUP's Current Ratio is ranked worse than 64.79% of 997
companies
in the Drug Manufacturers industry
Industry Median: 2
vs FRA:LUP: 1.53
Luye Pharma Group (FRA:LUP) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Luye Pharma Group Current Ratio Related Terms
Luye Pharma Group Current Ratio Historical Data
* Premium members only.
The historical data trend for Luye Pharma Group's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Luye Pharma Group's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Luye Pharma Group Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Luye Pharma Group's Current Ratio distribution charts can be found below:
* The bar in red indicates where Luye Pharma Group's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Luye Pharma Group (FRA:LUP) has a Current Ratio of 1.53 as of Dec. 2025. This is near median its historical median of 1.40. Over the past decade, Luye Pharma Group's Current Ratio has ranged from 1.06 to 2.22. According to the industry distribution chart, Luye Pharma Group ranks #646 out of 997 companies in the Drug Manufacturers industry, placing it in the top 64.8%.
Is Luye Pharma Group's Current Ratio too high?
Luye Pharma Group's current Current Ratio of 1.53 is near median its 10-year median of 1.40. Over the past 10 years, this metric has ranged from a low of 1.06 to a high of 2.22. The Drug Manufacturers industry median Current Ratio is 2.00. Luye Pharma Group's value of 1.53 is 23.5% below this industry median. Based on the distribution chart, Luye Pharma Group ranks #646 out of 997 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Luye Pharma Group has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Luye Pharma Group's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Luye Pharma Group ranks #646 out of 997 companies for Current Ratio. This places Luye Pharma Group in the lower half of its industry. The industry median Current Ratio is 2.00. Luye Pharma Group's value of 1.53 is 23.5% below this benchmark. Historically, Luye Pharma Group's own Current Ratio has ranged from 1.06 to 2.22 over the past decade. While the company's 10-year median is 1.40 vs. the industry median of 2.00, Luye Pharma Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Luye Pharma Group's current Current Ratio of 1.53 is 23.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Luye Pharma Group's current Current Ratio is 1.53, which is near median its own 10-year median of 1.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Luye Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Luye Pharma Group (FRA:LUP) is currently considered Possible Value Trap. The stock's GF Value™ is €0.32, compared to a current price of €0.20 — trading 36.3% below its estimated fair value. The current Current Ratio is 1.53, which is near median its 10-year median of 1.40 and 23.5% below the Drug Manufacturers industry median of 2.00. Luye Pharma Group's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Luye Pharma Group (FRA:LUP), the current Current Ratio is 1.53 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Luye Pharma Group (FRA:LUP) Overvalued in 2026?
Based on GuruFocus' analysis, Luye Pharma Group stock appears to be undervalued.
The current stock price of €0.20 is trading 36.3% below its estimated GF Value™ of €0.32.
GuruFocus considers Luye Pharma Group to be Possible Value Trap.
Key valuation signals for FRA:LUP:
Current Ratio: 1.53 (near median its 10-year median of 1.40)
GF Value™: €0.32 vs. price of €0.20 (36.3% below fair value)
Industry Position: 23.5% below the Drug Manufacturers median (#646 of 997)
No single metric tells the full story. See the FRA:LUP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, which derives maximum revenue; Cardiovascular system drugs; Alimentary tract and metabolism drugs; Central nervous system drugs; and others. Geographically, the group derives maximum revenue from Chinese Mainland, while it also has its presence in Asia (other than the Chinese mainland), European Union, and Other countries.
47GF Score
Get the complete analysis for FRA:LUP
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LUP has been successfully added to your 
